 PhaseBio Pharmaceuticals Inc NASDAQ: PHAS has signed BioVectra as its manufacturing partner for its bentracimab as it ushers the drug through Phase 3. PhaseBio licensed bentracimab from AstraZeneca plc NASDAQ: AZN, the maker of blood thinner Brilinta ticagrelor, in 2017. 